Research presented at the 2024 Conference on Retroviruses and Opportunistic Infections reveals that long-acting injectable antiretroviral therapy provides improved HIV suppression with minimal adverse effects, offering a promising alternative for adolescents and individuals struggling with daily oral regimens.
Research presented at the 2024 Conference on Retroviruses and Opportunistic Infections reveals that 4 children, treated with antiretroviral therapy within 48 hours of birth, have achieved over a year of HIV remission.
A recent study assessed the effectiveness of GeneXpert point-of-care testing in detecting chlamydia, gonorrhoea, and trichomonas, revealing promising results but highlighting concerns over sensitivity rates, particularly for trichomonas.
Recent findings affirm the safety of monthly dapivirine vaginal rings and daily oral PrEP with tenofovir disoproxil fumarate and emtricitabine in preventing HIV transmission among pregnant cisgender women.
Discover how neighborhood disadvantage affects menopause onset and implications for women's health, as revealed by recent research published in Menopause, the journal of The Menopause Society.
A recent study revealed the effectiveness of the AI tool MySTIRisk in pinpointing high-risk subgroups for HIV and other sexually transmitted infections, shedding light on improved risk assessment and testing accessibility.
A recent study compared the efficacy and safety of 5-mg versus 6-mg doses of dexamethasone in preventing neonatal respiratory distress syndrome in preterm births, shedding light on dosage optimization for improved neonatal outcomes.
A study examines the association between donor types and obstetrical and graft morbidity risks among pregnant kidney transplant recipients, revealing increased short- and long-term graft loss risk from pregnancy after deceased donor kidney transplant compared to living donor kidney transplant.
Discover how the REPRIEVE trial sheds light on the increased cardiovascular risk among HIV patients, urging updated risk assessment tools for diverse populations.
A recent study finds that, contrary to previous concerns, amniocentesis does not heighten the risk of mother-to-child transmission of hepatitis B virus among infants following a standardized immunoprophylaxis schedule.
Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.
A recent study reveals that while oxytocin dosage correlates with a slight uptick in postpartum hemorrhage (PPH) risk, the use of oxytocin augmentation doesn't significantly increase PPH or blood loss when compared to patients with similar obstetric profiles.
Walgreens and CVS pharmacies are set to dispense mifepristone in select states, aiming to address legal complexities and enhance accessibility amidst ongoing regulatory and legal battles.
A recent study revealed the efficacy of antibiotic therapy in reducing intraamniotic inflammation among patients experiencing idiopathic bleeding in the second trimester of pregnancy, shedding light on potential management strategies for this condition.
Discover how transverse relaxation time mapping, a sensitive magnetic resonance imaging-based technique, unveils the relationship between placental oxygenation and fetal brain development, shedding light on potential biomarkers for assessing fetal well-being.
A recent study revealed that adherence to plant-based diets among postmenopausal women does not correlate with hip fracture risk, challenging concerns about the impact of such diets on bone health.
Discover how recent research unveils platelet-rich plasma as a promising alternative treatment for various pelvic floor disorders, offering hope for improved quality of life for affected individuals.
A recent systematic review highlighted a half-dozen methods to improve antenatal STI screening in low- and middle-income countries in need of better options.
A recent study revealed the efficacy of tetrazole oteseconazole against fluconazole-resistant Candida biofilms, offering hope for recurrent candidiasis patients seeking alternative therapies.
Recent study reveals the need for customizable electronic partner notification platforms for gonorrhea and chlamydia, highlighting the need for tailored solutions to improve sexually transmitted infection partner services.
A randomized trial among young Kenya women showed the post-exposure prophylactic was insignificantly more effective in preventing chlamydia, gonorrhea and syphilis—largely due to inadherence.
Discover how metabolomics sheds light on potential biomarkers for early detection and treatment of Candida albicans-induced vulvovaginal candidiasis, offering crucial insights into the pathogenesis of this prevalent inflammatory condition.
Discover how low folic acid levels during pregnancy heighten the risk of adverse outcomes including miscarriage and preterm delivery.
A recent investigation finds comparable safety and effectiveness between intravenous and intramuscular oxytocin administration, suggesting intramuscular administration may be preferable for postpartum hemorrhage prevention.
A recent investigation sheds light on patient preferences and concerns regarding external cephalic version versus cesarean section for managing fetal malpresentation, revealing gaps in counseling and the desire for more information.
Misunderstandings surrounding bacterial vaginosis can delay treatment, but advancements such as XACIATO offer effective solutions, emphasizing the importance of open communication and continued research for comprehensive women's health care.
Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.
Enmetazobactam (Exblifep; Orchid Pharma) gains FDA approval for treating complicated urinary tract infections in adults after demonstrating superiority over piperacillin-tazobactam in clinical cure and microbiological eradication in a global phase 3 trial.
A recent investigation sheds light on the efficacy of hormone therapy in alleviating depressive symptoms associated with menopause, revealing potential benefits for women undergoing natural menopause.
The FDA has issued a Complete Response Letter for the New Drug Application of cefepime-taniborbactam, requesting additional chemistry, manufacturing, and controls data.
